Literature DB >> 7717727

[Important prognostic factors in surgically treated gastric cancer patients].

M Hiratsuka1, T Iwanaga, H Furukawa, T Yasuda, H Nakano, S Nakamori, H Ohigashi, M Kameyama, Y Sasaki, T Kabuto.   

Abstract

In order to clarify important factors in prognosis of patients with gastric cancer, 3,515 surgically treated cases were investigated. The survival rate varied widely depending on the curativity which strongly correlated with the stage of the disease. For example, such cases with peritoneal dissemination and hepatic metastasis have a poor prognosis. According to our multivariate investigation by Cox's proportional hazard model (SAS, PHREG procedure) based on resectable cases of gastric cancer, the most significant prognostic factor was lymph node metastasis with a ratio of risk 4.58, followed by the macroscopic-type cancer, ratio of risk 3.61, and depth of invasion, with the ratio of risk 2.22. It should be noted that such factors as macroscopic type of cancer turned out to be an important prognostic factor aside from those related with the stage of cancer, such as lymph node metastasis and depth of invasion. Type 4 gastric cancer had a markedly poor prognosis. Among all surgically treated patients, the histologic type was insignificant as a prognostic factor, however, when limited to mucosal cancer, the undifferentiated type had a higher lymph node metastasis rate than the differentiated type. This result suggests that the histologic type of cancer should be carefully considered in case of endoscopic treatment of gastric cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7717727

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  6 in total

1.  When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant?

Authors:  Isao Miyashiro; Ko Takachi; Yuichiro Doki; Osamu Ishikawa; Hiroaki Ohigashi; Kohei Murata; Yo Sasaki; Shingi Imaoka; Akihiko Nakaizumi; Akemi Takenaka; Hiroshi Furukawa; Masahiro Hiratsuka
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

2.  Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2.

Authors:  Isao Miyashiro; Hiroshi Furukawa; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Toshifusa Nakajima; Taira Kinoshita; Osamu Kobayashi; Kuniyoshi Arai
Journal:  Gastric Cancer       Date:  2011-02-19       Impact factor: 7.370

3.  FKBP10 Acts as a New Biomarker for Prognosis and Lymph Node Metastasis of Gastric Cancer by Bioinformatics Analysis and in Vitro Experiments.

Authors:  Li-Bao Gong; Chuang Zhang; Ruo-Xi Yu; Ce Li; Yi-Bo Fan; Yun-Peng Liu; Xiu-Juan Qu
Journal:  Onco Targets Ther       Date:  2020-07-28       Impact factor: 4.147

4.  A proposal of a practical and optimal prophylactic strategy for peritoneal recurrence.

Authors:  Masafumi Kuramoto; Shinya Shimada; Satoshi Ikeshima; Akinobu Matsuo; Hiroshi Kuhara; Kojiro Eto; Hideo Baba
Journal:  J Oncol       Date:  2012-02-08       Impact factor: 4.375

5.  Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric cancer.

Authors:  Shingo Togano; Masakazu Yashiro; Yuichiro Miki; Yurie Yamamato; Tomohiro Sera; Yukako Kushitani; Atsushi Sugimoto; Shuhei Kushiyama; Sadaaki Nishimura; Kenji Kuroda; Tomohisa Okuno; Mami Yoshii; Tatsuro Tamura; Takahiro Toyokawa; Hiroaki Tanaka; Kazuya Muguruma; Sayaka Tanaka; Masaichi Ohira
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

6.  MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer.

Authors:  Xiaohua Li; Ying Zhang; Yongquan Shi; Guanglong Dong; Jie Liang; Ying Han; Xin Wang; Qingchuan Zhao; Jie Ding; Kaichun Wu; Daiming Fan
Journal:  J Cell Mol Med       Date:  2011-09       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.